biosyn Arzneimittel GmbH and Axon Neuroscience have long enjoyed a trusting cooperation in the development of Axon’s therapeutic vaccine AADVac1 against Alzheimer’s disease.
The family-owned company based in Fellbach near Stuttgart is an important partner of the Czech biotechnology company. Axon Neuroscience relies on the carrier immunocyanine (modified KLH) produced by biosyn, which can be used as a carrier protein for modern vaccines.
KLH stands for Keyhole Limpet Hemocyanin, a protein that forms the blue blood pigment of the sea snail (Megathura crenulata). The isolated carrier immunocyanine is marketed by biosyn under the name VACMUNE®.
In order to ensure future supply in the larger required quantities and corresponding quality, the two companies are founding a joint venture. The corresponding contract was signed by both sides a few days ago.
Within the framework of the joint venture, two production plants for the manufacture of immunocyanine are to be built. A plant for the extraction of the starting material by a gentle puncture procedure, the haemolymph, is planned in Mexico.
The plant for further purification of the KLH and production of the immunocyanine will be built in Germany.
biosyn is contributing its production expertise, and Axon Neuroscience is involved as a strong financial partner. The family-owned company has been producing the carrier KLH for decades under the recognized rules of Current Good Manufacturing Practice (cGMP), which is what makes it suitable for human vaccines in the first place.
Axon has been developing a vaccine called AADvac1 for some time to stop Alzheimer’s disease. The vaccine is supposed to ensure that the tau protein, a component of the neurons, does not break down and thus no deposits occur. These are a central feature of Alzheimer’s and other neurodegenerative diseases in the brain. The study results so far with the potential vaccine AADvac1 give reason for hope. The vaccine showed an excellent safety profile and a statistically significant impact on neurodegeneration in a Phase II study recently published in Nature Aging.
Axon is now planning a phase III trial. And then the planned joint venture plays an important role in securing the long-term supply of the carrier for the potential vaccine after approval and market entry.
Axon Neuroscience
Axon Neuroscience was founded in 1999 by immunologist Professor Michal Novak. In 1988, Professor Novak discovered the tau protein as the main component of NFTs in Alzheimer’s disease while working at the Laboratory of Molecular Biology, MRC in Cambridge, UK.
Axon now has the world’s largest team dedicated exclusively to tau research, with more than 60 scientists and 15 senior scientists. Over the past two decades, Axon has published a large body of evidence showing that pathological tau is the main driver of Alzheimer’s disease.
Internetadresse von Axon Neuroscience:
https://axon-neuroscience.eu/
Anprechpartner:
George Salapa
+421 910 571 065
media@axon-neuroscience.eu
biosyn Arzneimittel GmbH | Contact:
Schorndorfer Straße 32
D-70734 Fellbach
Telefon: +49 (0) 711-575 32-00
Telefax: +49 (0) 711-575 32-99
